Evidence map›Paper›PMID 27913681›Full record

ReviewBiochemical Society transactions2016

The Borg family of Cdc42 effector proteins Cdc42EP1-5.

Aaron J Farrugia, Fernando Calvo

Open access · hybridAbstract readReview
In one paragraph

Review in Biochemical Society transactions, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Chemical Proteomics Reveals NMolecular & cellular proteomics : MCP · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Aaron J FarrugiaTumour Microenvironment Team, Division of Cancer Biology, Institute of Cancer Research, 237 Fulham Road, London SW2 6JB, U.K.
Fernando CalvoTumour Microenvironment Team, Division of Cancer Biology, Institute of Cancer Research, 237 Fulham Road, London SW2 6JB, U.K.
Institute of Cancer Research · GB

Funding

Cancer Research UKWorldwide Cancer Research 15-0273
6 · The paper itself

Abstract

Despite being discovered more than 15 years ago, the Borg (binder of Rho GTPases) family of Cdc42 effector proteins (Cdc42EP1-5) remains largely uncharacterised and relatively little is known about their structure, regulation and role in development and disease. Recent studies are starting to unravel some of the key functional and mechanistic aspects of the Borg proteins, including their role in cytoskeletal remodelling and signalling. In addition, the participation of Borg proteins in important cellular processes such as cell shape, directed migration and differentiation is slowly emerging, directly linking Borgs with important physiological and pathological processes such as angiogenesis, neurotransmission and cancer-associated desmoplasia. Here, we review some of these findings and discuss future prospects.

Indexed as

Adaptor Proteins, Signal TransducingCytoskeletal ProteinsCytoskeletonGTP-Binding Protein RegulatorsHumansModels, BiologicalMultigene Familyrho GTP-Binding ProteinsRNA-Binding ProteinsSignal TransductionAdaptor Proteins, Signal TransducingCDC42EP1 protein, humanCDC42EP2 protein, humanCDC42EP3 protein, humanCDC42EP4 protein, humanCDC42EP5 protein, humanCytoskeletal ProteinsGTP-Binding Protein Regulatorsrho GTP-Binding ProteinsRNA-Binding ProteinsBorgCdc42cytoskeletonRho GTPasesseptin

Identifiers

PMID27913681
PMCPMC5134998
OpenAlexW2557828923

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.